The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.

MLA

Rejeski, Kai, et al. “The CAR-HEMATOTOX Risk-Stratifies Patients for Severe Infections and Disease Progression after CD19 CAR-T in R/R LBCL.” Journal for Immunotherapy of Cancer, vol. 10, no. 5, May 2022. EBSCOhost, https://doi.org/10.1136/jitc-2021-004475.

APA

Rejeski, K., Perez, A., Iacoboni, G., Penack, O., Bücklein, V., Jentzsch, L., Mougiakakos, D., Johnson, G., Arciola, B., Carpio, C., Blumenberg, V., Hoster, E., Bullinger, L., Locke, F. L., von Bergwelt-Baildon, M., Mackensen, A., Bethge, W., Barba, P., Jain, M. D., & Subklewe, M. (2022). The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. Journal for Immunotherapy of Cancer, 10(5). https://doi.org/10.1136/jitc-2021-004475

Chicago

Rejeski, Kai, Ariel Perez, Gloria Iacoboni, Olaf Penack, Veit Bücklein, Liv Jentzsch, Dimitrios Mougiakakos, et al. 2022. “The CAR-HEMATOTOX Risk-Stratifies Patients for Severe Infections and Disease Progression after CD19 CAR-T in R/R LBCL.” Journal for Immunotherapy of Cancer 10 (5). doi:10.1136/jitc-2021-004475.